SCHEMBL432612

SCHEMBL432612

CCCCCCCCCCCCN(CCCN)CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
KDM5A P29375 2/20 0.45
PHF8 Q9UPP1 2/20 0.45
KDM4C Q9H3R0 1/20 0.45
TSHR P16473 6/20 0.45
TDP1 Q9NUW8 3/20 0.45
ALOX15 P16050 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.45
ADRA2A P08913 1/20 0.45
DRD1 P21728 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
CYP2C19 P33261 1/20 0.45
ADRA1A P35348 1/20 0.45
DRD3 P35462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831575 0.93 KDM5A (0.45) CA12CA1CA2CA4KDM5A
SCHEMBL9145682 0.93 KDM5A (0.45) CA12CA1CA2CA4KDM5A
SCHEMBL19945020 0.93 KDM5A (0.45) CA12CA1CA2CA4KDM5A
Hydrochloric Acid SCHEMBL4796163 0.91 KDM5A (0.44) KDM5APHF8KDM4CTSHRTDP1
SCHEMBL1881925 0.91 KDM5A (0.44) CA12CA1CA2CA4KDM5A
SCHEMBL7568504 0.90 TSHR (0.54) KDM5APHF8KDM4CTSHRTDP1
SCHEMBL19040769 0.90 TSHR (0.54) KDM5APHF8KDM4CTSHRTDP1
SCHEMBL19821298 0.90 TSHR (0.54) KDM5APHF8KDM4CTSHRTDP1
SCHEMBL11512199 0.90 TSHR (0.54) KDM5APHF8KDM4CTSHRTDP1
SCHEMBL19821297 0.90 TSHR (0.54) KDM5APHF8KDM4CTSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839626-B2 Composition and kits for inhibition of pathogenic microbial infection and methods of using the same ROCHAL TECHNOLOGIES LLC (US) 2023-12-12 US claimed
CN-115054529-A Amino acid type oil-control acne-removing facial cleanser 广东嘉丹婷日用品有限公司 2022-09-16 CN claimed
CN-114848523-A Double-tube facial cleanser 广东嘉丹婷日用品有限公司 2022-08-05 CN claimed
CN-113855606-A Ginger shampoo and preparation method thereof 西藏山南德诺农林产业开发有限责任公司 2021-12-31 CN claimed
EP-3220741-B1 COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME ROCHAL IND LLC (US) 2021-02-24 EP claimed
CN-111135108-A Compound preservative containing amino acid derivatives, preparation method thereof and cosmetics 广东迪美生物技术有限公司 2020-05-12 CN claimed
US-20170360825-A1 Composition and Kits for Inhibition of Pathogenic Microbial Infection and Methods of Using the Same ROCHAL INDUSTRIES, LLC (US) 2017-12-21 US claimed
CN-107410317-A Improve the diffusible wet tissue composition in wet tissue fabric and the wet tissue containing said composition 明进新科技股份有限公司 2017-12-01 CN claimed
EP-3220741-A1 COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME Rochal Industries, LLC (US) 2017-09-27 EP claimed
EP-2152845-B1 HARD SURFACE CLEANING COMPOSITION WITH HYDROPHILIZING AGENT AND METHOD FOR CLEANING HARD SURFACES SOLVAY USA INC (US) 2017-03-29 EP claimed
US-20020090349-A1 Process for the biocidal treatment of surface BERGERON VANCE (FR) 2002-07-11 US claimed
US-5886041-A SKIN DISORDERS TRISTRATA TECHNOLOGY, INC. (US) 1999-03-23 US claimed
US-5886042-A PREVENTION OF IRRITATION BY INCLUDING AN ORGANIC BUFFER, E.G AN AMINO ACID, DIPEPTIDE, CREATINE; SKIN DISORDERS; COSMETICS; PH TRISTRATA TECHNOLOGY, INC. (US) 1999-03-23 US claimed
US-5883128-A SKIN DISORDERS TRISTRATA TECHNOLOGY INC. (US) 1999-03-16 US claimed
US-5702688-A TREATING SKIN DISORDERS TRISTRATA TECHNOLOGY, INC. (US) 1997-12-30 US claimed
US-5690967-A MIXTURE CONTAINING AMPHOTERIC AGENT TRISTRATA TECHNOLOGY, INC. (US) 1997-11-25 US claimed
US-5684044-A MIXED WITH AMPHOTERIC OR PSEUDOAMPHOTERIC AGENT TRISTRATA, INCORPORATED (US) 1997-11-04 US claimed
US-5681853-A MIXTURE WITH AMPHOTERIC COMPOUND TRISTRATA TECHNOLOGY, INC. (US) 1997-10-28 US claimed
EP-0413528-B1 Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use YU RUEY J (US) 1995-11-15 EP claimed
US-5091171-A Skin disorders IGI, INC. 1992-02-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360825-A1 Composition and Kits for Inhibition of Pathogenic Microbial Infection and Methods of Using the Same CUTA, MMP8, MMP1 CA12 4094/4885CA1 4063/4885CA2 2919/4885
US-11839626-B2 Composition and kits for inhibition of pathogenic microbial infection and methods of using the same CUTA, MMP8, MMP1 CA12 4094/4885CA1 4063/4885CA2 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.